Illinois Municipal Retirement Fund Acquires 10,895 Shares of Halozyme Therapeutics, Inc. $HALO

Illinois Municipal Retirement Fund increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 47.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 33,957 shares of the biopharmaceutical company’s stock after purchasing an additional 10,895 shares during the period. Illinois Municipal Retirement Fund’s holdings in Halozyme Therapeutics were worth $2,490,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of HALO. Empowered Funds LLC bought a new position in Halozyme Therapeutics in the first quarter valued at approximately $755,000. Acadian Asset Management LLC bought a new stake in Halozyme Therapeutics in the 1st quarter valued at $195,000. Envestnet Portfolio Solutions Inc. lifted its position in Halozyme Therapeutics by 46.2% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 16,506 shares of the biopharmaceutical company’s stock valued at $859,000 after acquiring an additional 5,214 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $2,051,000. Finally, Legacy Wealth Asset Management LLC raised its stake in shares of Halozyme Therapeutics by 25.6% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 1,010 shares during the period. 97.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HALO. Weiss Ratings raised Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Morgan Stanley cut their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Citizens Jmp upped their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. upped their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $78.80.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares in the company, valued at $53,947,690.28. The trade was a 2.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 49,398 shares of company stock worth $3,650,592. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $79.44 on Monday. The company has a market capitalization of $9.34 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company has a 50-day simple moving average of $70.85 and a 200 day simple moving average of $69.96.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.